Advisory committee votes 17-4 to recommend FDA authorize Pfizer-BioNTech vaccine, opening door to rapid EUA
There were a million questions but little suspense.
For eight and a half hours, a panel of outside advisors debated Pfizer’s vaccine data, questioned endpoints, poked holes in post-authorization plans, interrogated safety signals and debated sub-groups, but in the end voted as most expected them to: recommending the FDA should OK Pfizer and BioNTech’s mRNA-based vaccine as the first inoculation for Covid-19 in the U.S.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
